ORCHPHARMA

Orchid Pharma Ltd., headquartered in Chennai, India, operates in the pharmaceutical and anti-infectives industries. The company is engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (FDF), with a particular focus on Cephalosporin antibiotics. It markets Enmetazobactam under the brand names EXBLIFEP and Orblicef. Orchid Pharma is noted as the only Indian pharmaceutical company with a New Chemical Entity approved in both the US and Europe. Its business activities include research on new drugs, including the development and approval of Enmetazobactam. The company serves markets in India, the US, and Europe. Orchid Pharma underwent a corporate insolvency resolution process and was acquired by the Dhanuka Group in 2020. Following this, the company has focused on high-value anti-infectives and global expansion. The company is listed under the ticker ORCHPHARMA.